Cipla’s API segment focuses on producing and supplying over 200 generic and complex APIs. The business supports global health initiatives and partners with generic companies for product development.
Products are distributed to more than 50 countries, with an emphasis on uninterrupted supply through strategic partnerships.
Clients include global pharmaceutical companies, particularly those focusing on generics, specialty APIs, and niche therapeutic areas.
The API market is experiencing steady growth due to increased drug approvals and demand for innovative treatments, particularly in oncology and biotechnology.
Competitors include other API manufacturers focusing on generics and specialty APIs. Cipla differentiates itself through its focus on niche APIs and strategic partnerships.
Cipla's API business must comply with stringent global regulations, including USFDA, EMA, and other country-specific standards, to ensure product quality and safety.
| Year | Revenue (USD million) | Growth Rate (%) | Gross Margin (%) |
|---|---|---|---|
| FY 2022-23 | 70.6 | 3% | 66.7% |
| FY 2023-24 | 70.1 | - | 66.7% |
This segment focuses on broadening access to quality medicines through generics and complex generics, addressing therapeutic areas like respiratory and peptides.
Primarily distributed across India, focusing on tier 2-6 cities, and increasingly in the U.S., which accounts for 26% of global revenues.
Hospitals, pharmacies, and healthcare professionals in India and international markets, especially the U.S., are key customers.
Global demand for generics is growing due to the expiration of drug patents and rising healthcare costs, providing growth opportunities in key therapeutic areas.
Competitors include generic pharmaceutical manufacturers. Cipla’s strong market presence in India and increasing penetration in the U.S. differentiates it from competitors.
Operations in this segment are subject to regulatory compliance with USFDA, DCGI (India), and other country-specific regulators to ensure safety and efficacy.
| Year | Operating Margin (%) | EBITDA Margin (%) |
|---|---|---|
| FY 2024 | 26% | 21.4% |
This segment is dedicated to leadership in chronic therapies such as respiratory, cardiac, and anti-diabetics. Cipla has built strong partnerships and focuses on branded prescriptions.
Products are distributed through pharmacies and healthcare facilities globally, with a focus on chronic disease management.
The customer base includes chronic disease patients, healthcare professionals, and pharmacies. Cipla has a strong presence in India and other emerging markets.
Global demand for chronic disease therapies is rising due to aging populations and increasing rates of chronic conditions like respiratory and cardiac diseases.
Competitors include global pharmaceutical companies with strong chronic therapy portfolios. Cipla’s established brand and innovative product offerings provide a competitive edge.
Cipla complies with global regulatory standards to ensure the safety and efficacy of its therapeutic products, especially in the chronic therapies sector.
| Year | EBITDA Margin (%) | Net Profit Margin (%) |
|---|---|---|
| FY 2023-24 | 24.5% | 16% |
Cipla plans to continue growing its therapeutic product portfolio, particularly in chronic therapies, and aims to leverage digital tools for enhanced market engagement.